A5041693706- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Blood donation and transfusion practices
- Hemophilia Treatment and Research
- HIV Research and Treatment
- Blood groups and transfusion
- HIV/AIDS Research and Interventions
- Parvovirus B19 Infection Studies
- Hemoglobinopathies and Related Disorders
- Hepatitis Viruses Studies and Epidemiology
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- Blood transfusion and management
- Platelet Disorders and Treatments
- T-cell and Retrovirus Studies
- Malaria Research and Control
- Blood Coagulation and Thrombosis Mechanisms
- Mosquito-borne diseases and control
- Virus-based gene therapy research
- Dermatological and COVID-19 studies
- Brucella: diagnosis, epidemiology, treatment
- Viral gastroenteritis research and epidemiology
- Cytomegalovirus and herpesvirus research
- Animal Disease Management and Epidemiology
University of Cambridge
2015-2024
Southern Medical University
2013-2023
Trinity House
2019
Institute for Transfusion Medicine
2000-2019
University of Chester
2016
Komfo Anokye Teaching Hospital
2003-2013
London School of Hygiene & Tropical Medicine
2013
Croatian Institute of Transfusion Medicine
2013
German Red Cross
2007-2013
Rigshospitalet
2013
The detection of hepatitis B virus (HBV) in blood donors is achieved by screening for surface antigen (HBsAg) and antibodies against core (anti-HBc). However, who are positive HBV DNA currently not identified during the window period before seroconversion. current use nucleic acid testing human immunodeficiency (HIV) C (HCV) RNA a single triplex assay may provide additional safety.
Using phylodynamic and phylogeographic methods, Angelos Hatzakis colleagues find that the global spread of Hepatitis C virus coincided with widespread use transfused blood expansion intravenous drug use.
The presence of human erythrovirus DNA in 2,440 blood donations from the United Kingdom and sub-Saharan Africa (Ghana, Malawi, South Africa) was screened. Sensitive qualitative real-time quantitative PCR assays revealed a higher prevalence persistent infection with simultaneous immunoglobulin G (IgG) viral (0.55 to 1.3%) than previously reported. This condition characterized by low load (median, 558 IU/ml; range, 42 135,000 IU/ml), antibody-complexed virus, free specific IgG, potentially...
The origin of hepatitis B virus (HBV) infection in humans and other primates remains largely unresolved. Understanding the HBV is crucial because it provides a framework for studying burden, subsequently evolution, pathogenicity with respect to changes human population size life expectancy. To investigate this controversy we examined relationship between phylogeny genetic diversity modern humans, investigated timescale global dispersal, tested hypothesis HBV-human co-divergence. We find that...
Background Occult hepatitis B virus ( HBV ) infection OBI is identified in 1:1000 to 1:50,000 E uropean blood donations. This study intended determine the infectivity of products from donors. Study Design and Methods Recipients previous donations donors were investigated through lookback (systematic retrieval recipients) or traceback (triggered by clinical cases). Serologic genomic studies undertaken on consenting recipients. Multiple variables potentially affecting examined. Results A total...
HBV infection by blood components is currently prevented in most developed countries combining sensitive surface antigen (HBsAg) assays, nucleic acid testing (NAT) and a few of them antibodies against the core (anti-HBc) screening. transmissions from three repeat donors tested negative for HBsAg DNA with highly screening test (limit detection (LOD): 3.4 IU/mL) were investigated.30 47 recipients produced these examined. Transfusion transmission was confirmed phylogenetic analysis viral...
Hepatitis C virus (HCV) infection is thought to mostly become chronic and rarely resolves. HCV was serologically screened in 4,984 samples from Ghanaian blood donors, 1.3% prevalence found. At least 53% of confirmed anti-HCV carriers had no detectable viral RNA were considered have cleared the recovered infection. Confirmation authenticated by presence antibodies specific at two antigens, NS3 E2. Reactivity core antigens lower than United Kingdom donors. The minority chronically infected...
BACKGROUND: In sub‐Saharan Africa, the percentage of screened blood is limited to approximately 75 percent for human immunodeficiency virus antibodies (anti‐HIV), 50 hepatitis B surface antigen, and 19 C (anti‐HCV), mainly because costs. STUDY DESIGN AND METHODS: 2002 2003, candidate donors were before donation HIV, HCV, (HBV) serologic markers with rapid tests. The efficacy this screening was assessed by nucleic acid testing (NAT) applied pools 10 plasma samples from donated units a...
To determine whether maternofetal transmission of hepatitis B virus (HBV) is a common route infection leading to chronic in west Africa, plasma samples, obtained at delivery from 1368 pregnant Ghanaian women and paired umbilical cord blood or newborn whole were tested for HBV surface antigen (HBsAg) DNA. A 16 % prevalence carriers, defined as detectable HBsAg and/or DNA, was found, >80 contained less than 1 x 10(4) IU ml(-1) DNA 99 infected with genotype E strains. documented 17 out 204 (8.3...
To investigate the molecular basis of occult hepatitis B virus (HBV) infection (OBI) in Asian blood donors.OBI donors from Hong Kong, Malaysia, Singapore, Taiwan and Thailand were tested for HBV serological markers, strains molecularly characterised.Among 138 confirmed OBI carriers (median age 47 years), genotypes C dominant (60% 34%, respectively) agreement with genotype distribution chronically infected region. Viral load ranged between unquantifiable 3670 IU/ml 11 IU/ml). Eleven per cent...
Tunisia is a medium-level epidemic country for hepatitis B virus (HBV). This study characterizes, the first time, full genome HBV strains from Tunisia. Viral load quantification and phylogenetic analyses of or pre-S/S sequences were performed on 196 surface antigen (HBsAg)-positive plasma samples Tunisian blood donors. The median viral was 64.65 IU ml(-1) (range<5-7.7x10(8) ml(-1)) 89% had loads below 10,000 ml(-1). Fifty-nine formed novel subgenotype D7, 41 clustered in D1, seven A2 one...
Background and Objectives West Africa is a highly endemic area for viral infections. The prevalence of five markers was determined in Ghanaian blood donors. Materials Methods Replacement volunteer donors were screened using enzyme immunoassays (EIAs) hepatitis B surface antigen (HBsAg), human immunodeficiency virus antibodies (anti‐HIV), HIV p24 antigen, T‐cell lymphocytotrophic virus‐I ‐II (anti‐HTLV‐I/II) C (anti‐HCV). Results HBsAg present at an equally high frequency (15%) young (median...
Blood donor screening for antibody to hepatitis B core antigen (anti‐HBc) implemented in some countries as a surrogate marker non‐A, non‐B has been superseded by anti‐HCV screening. To assess the value of anti‐HBc detection surface antigen‐negative blood donations that might contain infectious HBV, HBV genomic and recipient testing were used. screened confirmed multiple assays. Donations containing isolated those with anti‐hepatitis (anti‐HBs) level < 0.1 IU/ml tested presence DNA....
Nucleic acid testing (NAT) for hepatitis B virus (HBV) has been performed in Poland since 2005 on samples seronegative surface antigen (HBsAg), anti–hepatitis C (anti-HCV), and anti–human immunodeficiency (anti-HIV). Tools included 24-donation pool (PT) using Cobas Amplicor or individual donations (ID) by Procleix Ultrio. Seven of 761,666 (1:108,800) 21/250,191 (1:11,900) HBV DNA–positive were identified confirmed alternative methods. DNA load ranged between 11.6 4.6 × 104 IU/mL 11 could not...